The AKU Society in the UK is incredibly proud to announce that the European Commission (EC) has extended the existing marketing authorisation for nitisinone use in AKU. This is the culmination of years of hard work and dedication.
“We hope this decision means that patients across Europe will now begin to be able to access nitisinone. With this step, AKU no longer becomes a life sentence to pain and disability. We will continue to fight for patients’ access to the drug, across Europe and beyond. Thank you to everyone who has helped us reach this huge milestone. ”
Read the EC’s decision HERE.